The Global Human Microbiome Market is segmented by Type (Gastrointestinal Tract Human Micobiome, Urogenital Tract Human Micobiome), by Application (Diagnosis, Treatment): Opportunity Analysis and Industry Forecast, 2022–2028. It is published in Valuates Reports under the Biological Sciences Category.
The global Human Microbiome market size is projected to reach USD 1544.9 Million by 2028, from USD 384.9 Million in 2021, at a CAGR of 21.7% during 2022-2028.
Major factors driving the growth of the Human Microbiome Market:
The crucial factors that are responsible for the growth of the global Human Microbiome Market are the continuous rise in the number of lifestyle diseases, the rising focus on human Microbiome therapies, rapidly growing technological advancements in next-generation sequencing and metagenomics, etc.
TRENDS INFLUENCING THE GROWTH OF THE HUMAN MICROBIOME MARKET
The growing occurrence of lifestyle diseases provides the scope for healthcare professionals to rely on microbiome-based diagnostic tools. It is being used extensively for identifying the signatures of certain microorganisms, in turn, driving the growth of the microbiome market. The procedure usually involves recognizing DNA, RNA, metabolites, and proteins in combination with other biomarkers such as genetics to detect a particular disease and make a detailed prognosis.
Many culture-independent PCR techniques have evolved that enable quantitative and qualitative microbial identification. This has established metagenomic studies for detecting genes that allow microbes to influence hosts in unexpected ways fueling the expansion of the human microbiome market. A wide array of information is available such as pathogen surveillance, host-microbe interactions, and biotechnology. Potential links between the gut microbiome and diseases such as depression have been proposed. The biggest benefit of metagenomics lies in its nucleic aid extraction which can be done from any material in the environment.
The human gut microbiome plays a critical role in the efficiency of therapeutic compounds. Several studies estimate that the number of microbes present inside the human body can be beneficial for treating many diseases such as cancer and adopting novel therapies. This presents lucrative opportunities for drug developers and vaccine manufacturers surging the growth of the human microbiome market. Several key companies are getting funds to fasten the process of development of therapeutic drugs.
Public and private players in the healthcare industry are collaborating to expand their infrastructure for tackling the prevalence of diseases like diabetes, cancer, and obesity. Microbes are a rich source of enzymes that can be beneficial for novel therapeutics thereby gaining increasing government funds and grants to accelerate research initiatives. This will bolster the growth of the global human microbiome market. Additionally pharmaceutical and biotech companies are investing heavily in the development of the market.
HUMAN MICROBIOME MARKET SHARE ANALYSIS
Based on type, the gastrointestinal tract human microbiome segment will dominate in the human microbiome market share due to the increasing focus of industry players to develop therapeutic solutions for gut health disorders like irritable bowel syndrome and Crohn’s disorder.
Based on application, the diagnostics segment will witness considerable growth in the human microbiome market share due to innovations in genome mapping and the emergence of metagenomics technologies.Based on region, North America will be the most lucrative market owing to rising cases of lifestyle diseases, easy funding for microbiome research, and awareness of preventative healthcare procedures.
